sar425899 glucagon glp-1 dual agonist sanofi Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist Receptor occupancy of dual glucagon-like

The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).

DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006

Partner with GenScript today to advance your GLP-1 based therapeutics.

Here are our favorite products to support digestion, hydration, and comfort, plus expert-backed tips for finding relief.

Citing its post-market evaluation that found no increased risk of suicidal ideation or behavior, the U.S

Gastrointestinal (GI) adverse eventsparticularly nausea, vomiting, diarrhea, and constipationare the most common side effects, generally emerging during dose escalation and resolving over time